Prenetics Global Ltd
PRE, PRENW · Laboratory Analytical Instruments · EDGAR filings ↗
Grade
D47Fast-growing consumer-health brand (IM8) with strong top-line momentum but deep losses and negative cash flow.
Strengths
- Revenue growth 40.8% (100th pct); IM8 at ~$120M ARR shipping to 30+ countries
- Healthy gross margin 50% (53rd pct); $52M cash and ~7-quarter runway
- Subscription-led model (~80% of IM8 orders), focused after divestitures
Risks
- Deeply unprofitable: net margin -163% (18th pct), operating margin -157%
- Negative FCF -$29.9M; ROE -29%
- Brand/execution risk and Hong Kong/China-related exposure
Notable findings
- Net lossNet loss (net margin -162.7%)
- Cash burnNegative free cash flow (-29.9M)
Key metrics
Gross margin
50.3%
Operating margin
-157.2%
Net margin
-162.7%
Return on equity
-29.1%
Return on assets
-23.3%
Revenue growth (QoQ)
40.8%
Current ratio
2.4×
Free cash flow
-$30M
Tangible book value
$134M
Cash & investments
$52M
Cash runway
7q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-15 | Cheng Yin Pan | Option exercise | 16K | — |
| 2026-06-15 | VANDERVEEN DAVID | Option exercise | 6.9K | — |
All non-derivative Form 4 activity (SEC), newest first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-30 | 2025-12-31 | 0001628280-26-028623 ↗ |
| 20-F | 2025-04-30 | 2024-12-31 | 0001628280-25-021127 ↗ |
| 20-F | 2024-05-01 | 2023-12-31 | 0001628280-24-019411 ↗ |
| 20-F | 2023-05-01 | 2022-12-31 | 0001193125-23-130403 ↗ |
| 20-F | 2022-05-27 | 2022-05-18 | 0001104659-22-065839 ↗ |